ReAlta Life Sciences said it is presenting new data at the American Society of Hematology (ASH) Annual Meeting in San Diego, California for its drug candidate in acute Graft-versus-Host Disease (aGVHD), pegtarazimod.
The study showed significant improvement in survival rates, protective effects on intestinal tissue and 50% reduction in key inflammatory markers, the company stated.
“These data add to the comprehensive body of research supporting pegtarazimod’s therapeutic potential, as we advance our Phase 2 trial on a path towards addressing the pressing unmet need in aGVHD,” said Paolo Martini, ReAlta’s Chief Research and Development Officer.
Contact:
